Genetically engineered mesenchymal stem cells with dopamine synthesis for Parkinson’s disease in animal models
Abstract Although striatal delivery of three critical genes for dopamine synthesis by viruses is a potential clinical approach for treating Parkinson’s disease (PD), the approach makes it difficult to finely control dopamine secretion amounts and brings safety concerns. Here, we generate genetically...
Main Authors: | Jun Li, Nan Li, Jingkuan Wei, Chun Feng, Yanying Chen, Tingwei Chen, Zongyong Ai, Xiaoqing Zhu, Weizhi Ji, Tianqing Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-12-01
|
Series: | npj Parkinson's Disease |
Online Access: | https://doi.org/10.1038/s41531-022-00440-6 |
Similar Items
-
Generation of cortical neurons through large-scale expanding neuroepithelial stem cell from human pluripotent stem cells
by: Shumei Zhao, et al.
Published: (2020-10-01) -
Effect of TO901317 on GF to promote the differentiation of human bone marrow mesenchymal stem cells into dopamine neurons on Parkinson’s disease
by: Miaomiao Li, et al.
Published: (2021-03-01) -
VEGF-Expressing Mesenchymal Stem Cell Therapy for Safe and Effective Treatment of Pain in Parkinson’s Disease
by: Man Li, et al.
Published: (2023-01-01) -
Dopamine regulates mobilization of mesenchymal stem cells during wound angiogenesis.
by: Saurav Shome, et al.
Published: (2012-01-01) -
Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: A systematic review
by: Shu-fen Liu, et al.
Published: (2022-10-01)